Loading...

Aligos Therapeutics ($ALGS)

Stock Image

ALGS Overview

Aligos Therapeutics, a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis.Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. (From: StockAnalysis.com)

MORE ABOUT Aligos Therapeutics

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.

CONVERSATIONS ABOUT Aligos Therapeutics